HBM Holdings Limited (Harbour BioMed)

Harbour BioMed, operating under the legal entity HBM Holdings Limited, is a global biopharmaceutical company dedicated to the discovery and development of novel antibody therapeutics. The company's mission is to deliver "Healthy life · Breakthrough Medicines" by focusing on innovation in immunology, oncology, and other therapeutic areas. Headquartered in Suzhou, China, Harbour BioMed maintains a global footprint with operations in the United States, the Netherlands, and multiple locations across China.

Harbour BioMed leverages its proprietary antibody technology platforms, including Harbour Mice®, which generates fully human monoclonal antibodies, and HBICE® for HCAb-based immune cell engagers. The company also integrates advanced AI technologies, such as the Hu-mAtrIx™ AI platform, to accelerate drug discovery. Its robust and differentiated pipeline includes clinical-stage assets like Batoclimab (HBM9161) for autoimmune diseases, HBM4003 (Porustobart) for oncology, and HBM9378, a TSLP-targeting antibody, alongside other bispecifics, multispecifics, and antibody-drug conjugates. The company's therapeutic focus spans immunology, oncology, central nervous system disorders, and metabolic diseases.

Recent notable developments include the appointment of Dr. Adam Zong as President in April 2026 and the reporting of strong full-year 2025 financial results, highlighting sustained global collaborations. In late 2025 and early 2026, Harbour BioMed announced significant strategic partnerships, including agreements with Bristol Myers Squibb for multi-specific antibodies, Lannacheng for radionuclide drug conjugates, and an equity partnership with Solstice Oncology for HBM4003. The company also deepened its collaboration with Spruce Biosciences through a common stock acquisition. These collaborations underscore Harbour BioMed's strategy to expand its pipeline and market presence, positioning it as a platform-based biopharmaceutical leader.